These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 7508663

  • 1. [New concepts in therapy of type I allergic diseases].
    Valenta R, Steinberger P, Vrtala S, Grote M, Laffer S, Sperr WR, Valent P, Kraft D, Scheiner O.
    Wien Klin Wochenschr; 1993; 105(23):682-6. PubMed ID: 7508663
    [Abstract] [Full Text] [Related]

  • 2. Allergen-related approaches to immunotherapy.
    Rolland JM, Gardner LM, O'Hehir RE.
    Pharmacol Ther; 2009 Mar; 121(3):273-84. PubMed ID: 19111571
    [Abstract] [Full Text] [Related]

  • 3. Genetic engineering of pollen allergens for hayfever immunotherapy.
    Bhalla PL.
    Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
    [Abstract] [Full Text] [Related]

  • 4. Genetic allergen modification in the development of novel approaches to specific immunotherapy.
    Mutschlechner S, Deifl S, Bohle B.
    Clin Exp Allergy; 2009 Nov; 39(11):1635-42. PubMed ID: 19624521
    [Abstract] [Full Text] [Related]

  • 5. [Hyposensitization].
    Przybilla B, Ring J.
    Internist (Berl); 1991 Oct; 32(10):606-11. PubMed ID: 1761393
    [No Abstract] [Full Text] [Related]

  • 6. Recombinant allergen-specific antibody fragments: tools for diagnosis, prevention and therapy of type I allergy.
    Valenta R, Flicker S, Eibensteiner PB, Steinberger P, Laffer S, Dolecek C, Kraft D.
    Biol Chem; 1997 Aug; 378(8):745-9. PubMed ID: 9377468
    [Abstract] [Full Text] [Related]

  • 7. Immunological mechanisms of allergen-specific immunotherapy.
    Jutel M, Akdis CA.
    Allergy; 2011 Jun; 66(6):725-32. PubMed ID: 21466562
    [Abstract] [Full Text] [Related]

  • 8. Allergy diagnosis, allergen repertoires, and their implications for allergen-specific immunotherapy.
    Crameri R.
    Immunol Allergy Clin North Am; 2006 May; 26(2):179-89, v. PubMed ID: 16701139
    [Abstract] [Full Text] [Related]

  • 9. Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy.
    Valenta R, Vrtala S, Focke-Tejkl M, Bugajska-Schretter, Ball T, Twardosz A, Spitzauer S, Grönlund H, Kraft D.
    Biol Chem; 1999 May; 380(7-8):815-24. PubMed ID: 10494830
    [Abstract] [Full Text] [Related]

  • 10. Allergen-specific immunotherapy.
    Niederberger V.
    Immunol Lett; 2009 Feb 21; 122(2):131-3. PubMed ID: 19100771
    [Abstract] [Full Text] [Related]

  • 11. Synthetic and genetically engineered allergen derivatives for specific immunotherapy of type I allergy.
    Valenta R, Vrtala S, Focke-Tejkl M, Twardosz A, Swoboda I, Bugajska-Schretter A, Spitzauer S, Kraft D.
    Clin Allergy Immunol; 2002 Feb 21; 16():495-517. PubMed ID: 11577556
    [No Abstract] [Full Text] [Related]

  • 12. B-cell epitopes of allergens determined by recombinant techniques; use for diagnosis and therapy of type I allergy.
    Valenta R, Vrtala S, Laffer S, Steinberger P, Ball T, Ferreira F, Scheiner O, Kraft D.
    Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M; 1994 Feb 21; (87):235-46. PubMed ID: 7532944
    [Abstract] [Full Text] [Related]

  • 13. Strategies for converting allergens into hypoallergenic vaccine candidates.
    Vrtala S, Focke-Tejkl M, Swoboda I, Kraft D, Valenta R.
    Methods; 2004 Mar 21; 32(3):313-20. PubMed ID: 14962766
    [Abstract] [Full Text] [Related]

  • 14. The current state of recombinant allergens for immunotherapy.
    Pauli G, Malling HJ.
    Curr Opin Allergy Clin Immunol; 2010 Dec 21; 10(6):575-81. PubMed ID: 20859201
    [Abstract] [Full Text] [Related]

  • 15. Molecular and immunologic characterization of a highly cross-reactive two EF-hand calcium-binding alder pollen allergen, Aln g 4: structural basis for calcium-modulated IgE recognition.
    Hayek B, Vangelista L, Pastore A, Sperr WR, Valent P, Vrtala S, Niederberger V, Twardosz A, Kraft D, Valenta R.
    J Immunol; 1998 Dec 15; 161(12):7031-9. PubMed ID: 9862740
    [Abstract] [Full Text] [Related]

  • 16. Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens.
    Pittner G, Vrtala S, Thomas WR, Weghofer M, Kundi M, Horak F, Kraft D, Valenta R.
    Clin Exp Allergy; 2004 Apr 15; 34(4):597-603. PubMed ID: 15080813
    [Abstract] [Full Text] [Related]

  • 17. IgE-facilitated antigen presentation: role in allergy and the influence of allergen immunotherapy.
    Wilcock LK, Francis JN, Durham SR.
    Immunol Allergy Clin North Am; 2006 May 15; 26(2):333-47, viii-ix. PubMed ID: 16701148
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Peptide and recombinant immunotherapy.
    Larché M.
    Immunol Allergy Clin North Am; 2011 May 15; 31(2):377-89, xi. PubMed ID: 21530826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.